Since PD-1 is the direct target of anti-PD-1 agents such as pembrolizumab, it seems reasonable that the expression of PD-1 in the tumor immune microenvironment would be associated with response to anti-PD-1 therapy. The gene discussed is PDCD1; the disease is neoplasm.